Novel Treatment of Allergic Fungal Sinusitis Using Omalizumab

Abstract

A case report of recalcitrant allergic fungal sinusitis (AFS) refractory to systemic corticosteroids and multiple functional endoscopic sinus surgeries (FESSs) treated with anti-IgE antibody omalizumab is reported. AFS is often classified with chronic rhinosinusitis (CRS). Although similar symptoms are among the two diseases, AFS has a unique pathophysiology. Patients with AFS demonstrate type 1 hypersensitivity to fungal allergens, increased total serum IgE, increased CD8 + T-cell prevalence, and IL-4 and IL-5 response. Omalizumab should be considered in the treatment of AFS.